Trial Profile
Phase II randomized study of salvage therapy comparing nilotinib with dasatinib in patients with imatinib-resistant chornic phase chronic myeloid leukemia (JALSG CML210R Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2012
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 12 Sep 2011 New trial record